SCHEMBL1923607

SCHEMBL1923607

Cc1ccc2c(=O)c(-c3ccc(F)cc3)cn(CC(=O)Nc3cc(C)on3)c2c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.47
▸ CTSB P07858 1/20 0.47
▸ CTSK P43235 1/20 0.47
▸ PKM P14618 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP2C9 P11712 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ USP10 Q14694 1/20 0.43
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1923423 0.94 GAPDH (0.48) PKMMEN1KMT2AMAPK1LMNA
SCHEMBL1923430 0.91 USP10 (0.52) MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1
SCHEMBL4402775 0.90 USP10 (0.41) MAPK1LMNAALDH1A1USP10POLB
SCHEMBL1923429 0.83 MAPT (0.55) MEN1KMT2AMAPK1SMN1; SMN2LMNA
SCHEMBL1923571 0.82 KMT2A (0.49) MEN1KMT2AMAPK1LMNAALDH1A1
SCHEMBL27775283 0.81 MAPT (0.42) MEN1KMT2AMAPK1LMNAALDH1A1
SCHEMBL4408407 0.81 USP10 (0.50) MEN1KMT2AMAPK1SMN1; SMN2LMNA
SCHEMBL1923524 0.81 MAPT (0.55) MEN1KMT2AMAPK1SMN1; SMN2LMNA
SCHEMBL1923888 0.80 NPC1 (0.44) MEN1KMT2AMAPK1SMN1; SMN2LMNA
SCHEMBL1923303 0.80 AKR1A1 (0.44) MEN1KMT2AALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 — — EP claimed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 — — US claimed
EP-2064185-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS Ferrer Internacional, S.A. (ES) 2009-06-03 — — EP claimed
WO-2008017710-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL S.A. (ES) 2008-02-14 — — WO claimed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 — — EP claimed
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 — — EP disclosed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 — — US disclosed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS GABRA1, GABRA4, GABRA2 CTSL 4747/4885CTSB 4534/4885CTSK 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback